| Topic | System/Indication | Intervention/Mechanism | Key quantitative findings | Key limitations/safety | Source (citation id) |
|---|---|---|---|---|---|
| Core function and localization of human BCL2L1/BCL-xL | Human BCL2L1 / BCL-xL protein | Anti-apoptotic BCL-2 family protein; BH1-BH4 domains plus C-terminal transmembrane anchor; BH3-binding groove sequesters BH3-only proteins and inhibits BAX/BAK, preventing MOMP/cytochrome c release; localizes mainly to mitochondrial outer membrane, also ER, cytosol, and nuclear membrane/outer nuclear membrane | Major isoforms: Bcl-xL ~233 aa (anti-apoptotic) and Bcl-xS ~170 aa (pro-apoptotic); Q07817 explicitly mapped to BCL-xL in recent interactome reference | Functionally important in normal cell survival; on-target inhibition can damage platelets because platelets depend on BCL-xL | (pqac-00000001, pqac-00000009, pqac-00000010, pqac-00000012, pqac-00000014) |
| 2024 development: BRAF + BCL-XL targeting | BRAFV600E colorectal cancer | Encorafenib combined with BCL-XL inhibition/degradation (A-1331852, DT2216, AZD0466) to lower apoptotic threshold created by high basal BCL-XL/MCL-1 | Standard targeted therapy context: encorafenib + cetuximab gives ~20% objective responses and ~3.6-month OS benefit; encorafenib or encorafenib+cetuximab alone induced <25% apoptosis in cell lines; encorafenib + A-1331852 induced >50% apoptosis in 3/5 BRAFV600E CRC lines; MCL1 inhibitor combination exceeded 20% apoptosis in only 1/5 lines; encorafenib + AZD0466 caused significant xenograft suppression/regression and was well tolerated in mice | Some lines (HT29, RKO) were refractory; thrombocytopenia remains established on-target toxicity of BCL-XL inhibition; TUNEL signal not clearly different at sampled timepoint in vivo | (pqac-00000017, pqac-00000020, pqac-00000022, pqac-00000030) |
| 2024 development: splice-switching of BCL2L1 | Glioblastoma (GBM) | Splice-switching oligonucleotides / vivo-morpholino targeting BCLX pre-mRNA to shift splicing from anti-apoptotic Bcl-xL toward pro-apoptotic Bcl-xS | vMO/SSO tested at 2-8 uM (cells harvested 48 h; functional studies often 4-8 uM); shift lowered Bcl-xL/Bcl-xS ratio at mRNA and protein levels, triggered CASP9/CASP3-associated apoptosis, mitochondrial damage, autophagic flux, reduced 3D microsphere size, and enhanced radiosensitivity in 2D/3D GBM models | Quantitative percent splice-shift values were not given in the retrieved text; low-energy X-rays increased the Bcl-xL/Bcl-xS ratio, indicating some radiation regimens may favor the resistant isoform; normal astrocytes showed limited cytotoxicity in reported assays | (pqac-00000032, pqac-00000033, pqac-00000034) |
| 2024 development: BCL-XL dependency in pediatric leukemia | CBFA2T3::GLIS2 pediatric AMKL (also NUP98r AMKL models) | Genetic/functional vulnerability to BCL-XL targeted with navitoclax or selective BCL-XL PROTAC DT2216; combinations with low-dose cytarabine | Navitoclax or DT2216 induced apoptosis in vitro and in vivo; DT2216 dosed every 4 days for 4-6 weeks in xenograft models reduced circulating leukemic blasts and significantly prolonged survival; CG2 models were cytarabine-sensitive with IC50s of 1-7 nM; combinations further reduced leukemic burden | Retrieved text did not provide human response rates; navitoclax has known thrombocytopenia liability; DT2216 was developed to reduce this issue; minimal cross-toxicity reported on normal cord-blood CD34+ HSPCs in these models | (pqac-00000018, pqac-00000021, pqac-00000040, pqac-00000044) |
| Clinical translation: first-in-human DT2216 monotherapy trial | Relapsed/refractory malignancies (solid + hematologic), NCT04886622 | Phase 1 open-label dose-escalation/cohort-expansion of IV DT2216, a BCL-XL PROTAC degrader | Enrollment 20; started 2021-08-25; completed June 2024; DT2216 IV over 30 min twice weekly on a continuous 28-day cycle; starting dose 0.04 mg/kg with escalation; PK/PD included Cmax, half-life, clearance, PBMC BCL-XL levels, serial platelet counts | DLT criteria explicitly included Grade 4 thrombocytopenia and Grade 3 thrombocytopenia with clinically significant hemorrhage; no efficacy outcomes were provided in the retrieved trial text | (pqac-00000025, pqac-00000027, pqac-00000029) |
| Clinical translation: pediatric/AYA combination trial | Relapsed/refractory solid tumors and fibrolamellar carcinoma, NCT06620302 | Phase I/II DT2216 + irinotecan; BCL-xL degradation plus chemotherapy | Recruiting; estimated enrollment 81; DT2216 IV on days 1, 4, 8, 11, 15, 18 plus irinotecan on days 2-6 in cycle 1 then days 1-5 thereafter; 21-day cycles; PD includes PBMC Bcl-xL levels and paired tumor IHC when available | Primary goals are toxicity, MTD/RP2D, PK, preliminary activity; retrieved text did not include results or specific thrombocytopenia rates | (pqac-00000028, pqac-00000043) |
| Clinical translation: ovarian cancer combination trial | Platinum-resistant ovarian cancer, NCT06964009 | Phase 1b dose-escalation of DT2216 + weekly paclitaxel | Recruiting; estimated enrollment ~30; primary aims are MTD/RP2D and DLTs during cycle 1/up to start of cycle 2 | DLTs include Grade >=3 non-hematologic and selected hematologic toxicities, treatment delays >14 days, death, or inability to receive >=75% of assigned doses; no outcome data yet in retrieved record | (pqac-00000026) |
| Platelet-sparing rationale for PROTAC BCL-XL targeting | Cross-indication translational strategy | DT2216 links a BCL-XL-binding warhead to a VHL ligand so degradation is favored in VHL-expressing tumor cells, while platelets with minimal/low VHL expression are relatively spared | Preclinical rationale only in retrieved sources: DT2216 showed dose-dependent BCL-XL degradation in CRC models and was specifically designed/developed to limit thrombocytopenia | Human platelet-sparing efficacy still requires clinical confirmation; thrombocytopenia remains a prespecified safety concern and is closely monitored in trials | (pqac-00000017, pqac-00000039, pqac-00000040) |


*Table: This table condenses the main functional annotation points for human BCL2L1/BCL-xL and highlights the most relevant 2024 mechanistic, therapeutic, and clinical-translation findings. It is useful as a quick reference linking core biology to current drug-development efforts and available quantitative evidence.*